Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults (PNOC029)

Primary Investigator
Franson, Andrea
Status
OPEN TO ACCRUAL
Phase
II
NCT Number
NCT05465174
UM Number
2023.053
Age Group
Both
Management Group
CTSU - Michigan
Oncology Group
Childhood Cancers
ID (Protocol)
47257
Secondary Protocol No
HUM00234744
Scope
National
Sponsor Type
Institutional
Disease Site
Brain and Nervous System
Summary
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

Eligibility: